EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 3.0

Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial

Yuncheng Ni, Ranglang Huang, Shuang Yang, Xiao Yan Yang, Shan Zeng, An Yao, Jie Huang, Guoping Yang iD

Drug Design, Development and Therapy · 2024-07 · Volume 18 · 2729-2743

DOI: 10.2147/dddt.s461416 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2024-07. Verfasst von Yuncheng Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan, 410013, People's Republic o…. Hauptthemen laut MEDLINE: Chronic Pain, Dose-Response Relationship, Drug, Spiro Compounds, Thiophenes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic PainDose-Response Relationship, DrugSpiro CompoundsThiophenesAdultFemaleHumansMaleMiddle AgedYoung AdultChinaEast Asian People

Stichwörter der Autor:innen

G-protein-biased ligandchronic painoliceridinepharmacokineticsphase I trial

Substanzen

((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineSpiro CompoundsThiophenes

Autor:innen und Institutionen

  • Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China.
  • Department of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China.
  • Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.

ORCID-Profile: Guoping Yang

Zitieren

APA

Ni, Y., Huang, R., Yang, S., Yang, X. Y., Zeng, S., Yao, A., Huang, J., & Yang, G. (2024). Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial. Drug Design, Development and Therapy, Volume 18, 2729-2743. https://doi.org/10.2147/dddt.s461416

Vancouver

Ni Y, Huang R, Yang S, Yang XY, Zeng S, Yao A, et al. Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial. Drug Design, Development and Therapy. 2024;Volume 18:2729-2743. doi:10.2147/dddt.s461416

BibTeX
@article{Ni2024,
  author = {Ni, Yuncheng and Huang, Ranglang and Yang, Shuang and Yang, Xiao Yan and Zeng, Shan and Yao, An and Huang, Jie and Yang, Guoping},
  title = {Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  volume = {Volume 18},
  pages = {2729--2743},
  doi = {10.2147/dddt.s461416}
}
Kostenlos starten →